UNIVERSAL TECHNICAL INSTITUT (UTI) Stock Fundamental Analysis

NYSE:UTI • US9139151040

30.35 USD
+1.96 (+6.9%)
At close: Feb 13, 2026
30.35 USD
0 (0%)
After Hours: 2/13/2026, 7:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

UTI gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 75 industry peers in the Diversified Consumer Services industry. UTI has an excellent profitability rating, but there are some minor concerns on its financial health. While showing a medium growth rate, UTI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year UTI was profitable.
  • UTI had a positive operating cash flow in the past year.
  • In the past 5 years UTI has always been profitable.
  • In the past 5 years UTI always reported a positive cash flow from operatings.
UTI Yearly Net Income VS EBIT VS OCF VS FCFUTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M

1.2 Ratios

  • With a decent Return On Assets value of 6.44%, UTI is doing good in the industry, outperforming 69.33% of the companies in the same industry.
  • UTI's Return On Equity of 15.98% is fine compared to the rest of the industry. UTI outperforms 74.67% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 8.69%, UTI is in the better half of the industry, outperforming 76.00% of the companies in the same industry.
  • UTI had an Average Return On Invested Capital over the past 3 years of 7.27%. This is below the industry average of 10.20%.
  • The last Return On Invested Capital (8.69%) for UTI is above the 3 year average (7.27%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 6.44%
ROE 15.98%
ROIC 8.69%
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
UTI Yearly ROA, ROE, ROICUTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20 -30

1.3 Margins

  • Looking at the Profit Margin, with a value of 6.28%, UTI is in the better half of the industry, outperforming 64.00% of the companies in the same industry.
  • UTI's Profit Margin has improved in the last couple of years.
  • UTI has a better Operating Margin (8.38%) than 64.00% of its industry peers.
  • UTI's Operating Margin has improved in the last couple of years.
  • UTI has a Gross Margin of 49.62%. This is comparable to the rest of the industry: UTI outperforms 56.00% of its industry peers.
  • In the last couple of years the Gross Margin of UTI has declined.
Industry RankSector Rank
OM 8.38%
PM (TTM) 6.28%
GM 49.62%
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
UTI Yearly Profit, Operating, Gross MarginsUTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), UTI is creating some value.
  • The number of shares outstanding for UTI has been increased compared to 1 year ago.
  • Compared to 5 years ago, UTI has more shares outstanding
  • The debt/assets ratio for UTI has been reduced compared to a year ago.
UTI Yearly Shares OutstandingUTI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
UTI Yearly Total Debt VS Total AssetsUTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • UTI has an Altman-Z score of 3.43. This indicates that UTI is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.43, UTI is in the better half of the industry, outperforming 78.67% of the companies in the same industry.
  • UTI has a debt to FCF ratio of 6.28. This is a slightly negative value and a sign of low solvency as UTI would need 6.28 years to pay back of all of its debts.
  • UTI has a better Debt to FCF ratio (6.28) than 73.33% of its industry peers.
  • UTI has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
  • UTI's Debt to Equity ratio of 0.29 is in line compared to the rest of the industry. UTI outperforms 54.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 6.28
Altman-Z 3.43
ROIC/WACC1.03
WACC8.46%
UTI Yearly LT Debt VS Equity VS FCFUTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 1.14 indicates that UTI should not have too much problems paying its short term obligations.
  • UTI has a Current ratio (1.14) which is in line with its industry peers.
  • A Quick Ratio of 1.14 indicates that UTI should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.14, UTI perfoms like the industry average, outperforming 52.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 1.14
UTI Yearly Current Assets VS Current LiabilitesUTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • UTI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
  • UTI shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 65.96% yearly.
  • The Revenue has grown by 12.59% in the past year. This is quite good.
  • Measured over the past years, UTI shows a very strong growth in Revenue. The Revenue has been growing by 22.67% on average per year.
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%

3.2 Future

  • The Earnings Per Share is expected to grow by 6.67% on average over the next years.
  • Based on estimates for the next years, UTI will show a quite strong growth in Revenue. The Revenue will grow by 9.17% on average per year.
EPS Next Y-31.68%
EPS Next 2Y-11.51%
EPS Next 3Y6.67%
EPS Next 5YN/A
Revenue Next Year9.25%
Revenue Next 2Y8.99%
Revenue Next 3Y9.17%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
UTI Yearly Revenue VS EstimatesUTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M 1B
UTI Yearly EPS VS EstimatesUTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 31.29 indicates a quite expensive valuation of UTI.
  • UTI's Price/Earnings ratio is in line with the industry average.
  • When comparing the Price/Earnings ratio of UTI to the average of the S&P500 Index (27.97), we can say UTI is valued inline with the index average.
  • A Price/Forward Earnings ratio of 34.00 indicates a quite expensive valuation of UTI.
  • UTI's Price/Forward Earnings is on the same level as the industry average.
  • The average S&P500 Price/Forward Earnings ratio is at 27.96. UTI is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 31.29
Fwd PE 34
UTI Price Earnings VS Forward Price EarningsUTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • UTI's Enterprise Value to EBITDA ratio is in line with the industry average.
  • Based on the Price/Free Cash Flow ratio, UTI is valued a bit cheaper than the industry average as 61.33% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 103.47
EV/EBITDA 13.56
UTI Per share dataUTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The decent profitability rating of UTI may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.47
EPS Next 2Y-11.51%
EPS Next 3Y6.67%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for UTI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

UNIVERSAL TECHNICAL INSTITUT

NYSE:UTI (2/13/2026, 7:00:00 PM)

After market: 30.35 0 (0%)

30.35

+1.96 (+6.9%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)02-04
Earnings (Next)05-05
Inst Owners97.52%
Inst Owner Change5.11%
Ins Owners2.78%
Ins Owner Change5.04%
Market Cap1.67B
Revenue(TTM)855.03M
Net Income(TTM)53.69M
Analysts81.82
Price Target38.18 (25.8%)
Short Float %5.03%
Short Ratio3.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.03
Dividend Growth(5Y)-34.43%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.57%
Min EPS beat(2)28.91%
Max EPS beat(2)66.22%
EPS beat(4)4
Avg EPS beat(4)59.42%
Min EPS beat(4)28.91%
Max EPS beat(4)73.27%
EPS beat(8)7
Avg EPS beat(8)48.68%
EPS beat(12)11
Avg EPS beat(12)85.96%
EPS beat(16)14
Avg EPS beat(16)183.11%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.47%
Max Revenue beat(2)0.82%
Revenue beat(4)4
Avg Revenue beat(4)1.74%
Min Revenue beat(4)0.47%
Max Revenue beat(4)4.51%
Revenue beat(8)8
Avg Revenue beat(8)2.01%
Revenue beat(12)12
Avg Revenue beat(12)2.35%
Revenue beat(16)15
Avg Revenue beat(16)2.9%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-42.84%
EPS NY rev (1m)0%
EPS NY rev (3m)-16.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.03%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.93%
Valuation
Industry RankSector Rank
PE 31.29
Fwd PE 34
P/S 1.95
P/FCF 103.47
P/OCF 21.56
P/B 4.97
P/tB 5.83
EV/EBITDA 13.56
EPS(TTM)0.97
EY3.2%
EPS(NY)0.89
Fwd EY2.94%
FCF(TTM)0.29
FCFY0.97%
OCF(TTM)1.41
OCFY4.64%
SpS15.54
BVpS6.11
TBVpS5.21
PEG (NY)N/A
PEG (5Y)0.47
Graham Number11.54
Profitability
Industry RankSector Rank
ROA 6.44%
ROE 15.98%
ROCE 11.63%
ROIC 8.69%
ROICexc 11.82%
ROICexgc 13.27%
OM 8.38%
PM (TTM) 6.28%
GM 49.62%
FCFM 1.89%
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
ROICexc(3y)10.21%
ROICexc(5y)8.25%
ROICexgc(3y)11.54%
ROICexgc(5y)9.21%
ROCE(3y)9.72%
ROCE(5y)7.88%
ROICexgc growth 3Y34.26%
ROICexgc growth 5YN/A
ROICexc growth 3Y33.76%
ROICexc growth 5YN/A
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
F-Score7
Asset Turnover1.03
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 6.28
Debt/EBITDA 0.93
Cap/Depr 181.06%
Cap/Sales 7.17%
Interest Coverage 250
Cash Conversion 73.39%
Profit Quality 30.06%
Current Ratio 1.14
Quick Ratio 1.14
Altman-Z 3.43
F-Score7
WACC8.46%
ROIC/WACC1.03
Cap/Depr(3y)145.01%
Cap/Depr(5y)268.95%
Cap/Sales(3y)5.89%
Cap/Sales(5y)11.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
EPS Next Y-31.68%
EPS Next 2Y-11.51%
EPS Next 3Y6.67%
EPS Next 5YN/A
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
Revenue Next Year9.25%
Revenue Next 2Y8.99%
Revenue Next 3Y9.17%
Revenue Next 5YN/A
EBIT growth 1Y-0.64%
EBIT growth 3Y47.33%
EBIT growth 5YN/A
EBIT Next Year46.16%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y371.76%
FCF growth 3YN/A
FCF growth 5Y99.08%
OCF growth 1Y35.47%
OCF growth 3Y28.35%
OCF growth 5Y54.57%

UNIVERSAL TECHNICAL INSTITUT / UTI FAQ

What is the fundamental rating for UTI stock?

ChartMill assigns a fundamental rating of 5 / 10 to UTI.


What is the valuation status for UTI stock?

ChartMill assigns a valuation rating of 3 / 10 to UNIVERSAL TECHNICAL INSTITUT (UTI). This can be considered as Overvalued.


Can you provide the profitability details for UNIVERSAL TECHNICAL INSTITUT?

UNIVERSAL TECHNICAL INSTITUT (UTI) has a profitability rating of 7 / 10.


Can you provide the financial health for UTI stock?

The financial health rating of UNIVERSAL TECHNICAL INSTITUT (UTI) is 5 / 10.


What is the earnings growth outlook for UNIVERSAL TECHNICAL INSTITUT?

The Earnings per Share (EPS) of UNIVERSAL TECHNICAL INSTITUT (UTI) is expected to decline by -31.68% in the next year.